Camallergy’s mission is to develop life-changing treatments for people with food allergies. Its lead product treats peanut allergy, a serious and increasingly prevalent disease with no licensed treatment. Camallergy was an EIS investment opportunity.
Camallergy raised £815,075 via SyndicateRoom in November 2017.
According to a 2015 study, peanut allergy affects 1.5% of children in the UK and approximately 0.5% of adults in high-income countries in Europe suffer the same allergy.
Peanut allergy is the most common cause of severe reactions and food allergy deaths. The psychological effects of the risk of accidental exposure can be significant and children who are allergic to peanuts have been shown to experience reduced quality of life as a result.
Camallergy’s lead product, CA002, is an oral immunotherapy drug which desensitises patients by gradual exposure to increasing amounts of characterised peanut allergens and involves seven short treatment visits and two years of easy, daily administration.
Camallergy is a virtual company led by three co-founders: CEO Sherden Timmins and two key opinion leaders in the field of allergy, Dr Pamela Ewan and Dr Andrew Clark. Together with two employees, the team manages leading contract research organisations and a team of ~20 consultants with extensive drug development expertise.
How it works
CAoo2 aims to treat peanut allergy, following a patented updosing regimen. Patients undergo a 14-week updosing period to reach protection, which consists of seven dose steps incrementing fortnightly. The first of each updose is given in an allergy clinic and is followed by daily self-adminstration by the patient at home. The initial dose is tiny, increasing incrementally to a dose equivalent to approximately two whole peanuts by the final visit. Each dose is presented in a single capsule which is opened and poured out into food such as a yoghurt. After the 14 weeks, the patient takes a daily maintenance dose for two years and thereafter takes a weekly dose.
After this 14-week treatment period, patients can eat food freely without fear of reacting to peanut contamination. The treatment is designed to be minimally disruptive, with seven short visits, and uses a simple to take formulation that is easy to fit into patients’ daily routine.
After confirming results in a Phase 3 study, Camallergy intends to file for regulatory licences to make this treatment widely available worldwide. Early clinical evidence suggests the treatment approach may also work for other allergens.
The lead investor
In 1998 Jonathan Milner founded Abcam with David Cleevely and Professor Tony Kouzarides. The life-science company supplies the rapidly growing market for antibodies and other research tools. Abcam has grown to be a company worth over £2bn, employing more than 900 people worldwide.
In addition to being an experienced entrepreneur and business leader, Jonathan is also a business angel with a passion for supporting UK life-science and high-tech startups
When it comes to investing, Jonathan admits that due to his experience and expertise in life sciences, the vast majority of his investments are in this space. This is because it is a sector in which he finds he can add the most value to companies.
It is this real-world data and proven level of success that gives me confidence in Camallergy’s product and de-risks the investment from a technical perspective. This proven efficacy in the context that there is currently no treatment available leads me to believe that there is a huge market opportunity for Camallergy.
Camallergy lead investor